Moderna signs cancer vaccine deal with China-based CARsgen
Maddie Meyer/Getty Images News

Moderna (NASDAQ:MRNA) has agreed to develop its Claudin18.2 mRNA cancer vaccine with CARsgen Therapeutics (OTCPK:CRTHF) Claudin18.2 CAR T-cell candidate, CT041, the Chinese biotech announced Monday.
Per the terms, the companies expect to conduct a pre-clinical trial and a Phase 1 trial to study CT041 with Modernaâs Claudin18.2 mRNA cancer vaccine.

The off-the-shelf mRNA cancer vaccine is designed to code for the Claudin 18.2 protein, an antigen associated with tumors.
CT041, also known as satricabtagene autoleucel, is targeted at gastric carcinoma and other cancers linked to the digestive system. The autologous CAR T-cell product is currently undergoing multiple clinical trials in China and North America.
"Claudin18.2 is a promising therapeutic target to potentially treat multiple cancer types with high unmet medical need," said Dr. Lin Guey, Modernaâs (MRNA) Chief Scientific Officer of External Research Ventures.
The partnership comes as the Cambridge, Massachusetts-headquartered biotech eyes a commercial launch of its late-stage messenger-RNA-based cancer shot, mRNA-4157, in 2025.



More on Moderna

Moderna: Buy Before The Fall Covid-19 Wave
Moderna Falling As Vaccine Hesitancy Rises

Moderna, Inc. (MRNA) Q2 2023 Earnings Call Transcript
Moderna, Inc. 2023 Q2 - Results - Earnings Call Presentation
Moderna updated COVID-19 vaccine effective against Eris, Fornax variants
Moderna hires former UK government health official